Bempedoic acid

Таблетки, покрытые пленочной оболочкой By prescription

ATP-citrate lyase inhibitor – the first oral hypolipidemic drug of a new class for lowering LDL-C levels – “not a statin”

Bempedoic acid

Indications

Bempedoic acid is indicated for the treatment of adult patients with primary hyper-cholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia as an addition to the diet:

• in combination with drugs of the statin group or statins used in conjunction with other hypolipidemic drugs in patients unable to achieve target low-density lipoprotein cholesterol levels;

• as monotherapy or in combination with other hypolipidemic drugs in patients with intolerance to statins or in patients for whom they are contraindicated.

 

If there is no improvement or you feel worsening, you should consult a doctor.

Contraindications

Do not take Bempedoic acid:

- if you are allergic to bempedoic acid or any other ingredients of the drug listed in section 6 of the package insert sheet;

- if you are pregnant;

- if you are breast-feeding;

- if you are taking simvastatin (a medicine from the group of statins used to lower bad cholesterol in the blood) in doses of more than 40 mg per day.

Usage

Always take this medicine in full accordance with the advice of your doctor. If in doubt, consult your doctor.

Recommended dose

The recommended dose of Bempedoic acid is one film-coated tablet (180 mg) once a day.

If you are prescribed concomitant use of Bempedoic Acid and simvastatin, the recommended dose of simvastatin is 20 mg daily. Your doctor may increase your simvastatin dose to 40 mg per day depending on your condition.

If you have serious kidney or liver problems your doctor will monitor your condition. You may be prescribed additional tests.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.